Drug
Lumicitabine clinical trials
Also written ALS-008176.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Janssen Research & Development, LLC (8) · Alios Biopharma Inc. (4) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Piperacillin, Tazobactam Drug Combination (1)
Studies
Open first, then newest update. How each study uses lumicitabine is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial VirusCompletedPhase 2Alios Biopharma Inc.NCT02673476Written as ALS-008176
- A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge ModelCompletedPhase 2Alios Biopharma Inc.NCT02094365Written as ALS-008176
- Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02813460Written as Formulation A (ALS-008176)
- A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept FormulationsCompletedPhase 1Janssen Research & Development, LLCNCT03010059Written as JNJ-64041575 (oral suspension formulation)
- A Study of ALS-008176 in Infants Hospitalized With RSVCompletedPhase 1Alios Biopharma Inc.NCT02202356Written as ALS-008176
- A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT03332459Written as Lumicitabine
- Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial VirusTerminatedPhase 2Janssen Research & Development, LLCNCT02935673Written as lumicitabine
- A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial VirusTerminatedPhase 2Janssen Research & Development, LLCNCT03333317Written as Lumicitabine
- Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human MetapneumovirusWithdrawnPhase 2Janssen Research & Development, LLCNCT03502694Written as Lumicitabine
- A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsTerminatedPhase 1Janssen Research & Development, LLCNCT03468777Written as Lumicitabine
- A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03441529Written as Lumicitabine
- Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersCompletedPhase 1Alios Biopharma Inc.NCT01906164Written as ALS-008176
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT02478333Written as ALS-008176 (250 mg)
Given in every arm · 2 — lumicitabine is usual care beside what is tested
- Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02833831Written as ALS-008176
- A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176CompletedPhase 1Alios Biopharma Inc.NCT02231671Written as ALS-008176
Codes
What other systems call lumicitabine · ClinicalTrials.gg INT000221
- UNII (FDA) BNW5PQ52G1LUMICITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27274772lumicitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174641LumicitabineOne source FDA
- DrugBank DB14808One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BNW5PQ52G1 | LUMICITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27274772 | lumicitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174641 | Lumicitabine | One source FDA |
| DrugBank | DB14808 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.